Literature DB >> 20506003

Features of papillary thyroid microcarcinoma in the presence and absence of lymphocytic thyroiditis.

Hee Sung Kim1, Yoon Jung Choi, Ji-Sup Yun.   

Abstract

It is known that the prevalence of lymphocytic thyroiditis (LT) is higher in patients with papillary thyroid carcinoma (PTC), that gender influences this association, and that certain features of PTC occur more frequently in patients who also have LT. These relationships have not been studied in patients with papillary thyroid microcarcinomas (PTMC), however. Therefore, we performed a study to compare the clinical and pathological features of patients with PTMC who did and did not have LT. We collected the 323 consecutive patients following excision of PTMC diagnosed as papillary carcinoma on preoperative needle aspiration cytology. We analyzed the demographic, serologic, and pathologic data of those cases with categorization into four groups based on presence of LT and neck lymph node metastasis. In all PTMC, the presence of LT did not influence the frequency of lymph node metastasis (27 of 105 [25.7%] vs. 48 of 218 [22.0%]). Among the patients with metastatic PTMC, LT was noted significantly more often in female than male patients (95.2% vs. 79.8%). In metastatic PTMC, multifocality and bilaterality was more frequent in with LT than without LT (44.4% vs. 29.2%; 29.6% vs. 14.6%). Both the presence of serum thyroglobulin antibody (TgAb; p = 0.016) and serum microsomal antibody (p = 0.013) were highly correlated with the presence of LT. Twenty-seven of 105 patients (25.7%) with PTMC with LT had nodal metastasis. Co-existing LT was noted predominantly in women, influenced more often multifocality and bilaterality of tumors, and higher frequency of metastasis to lateral compartment lymph nodes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20506003     DOI: 10.1007/s12022-010-9124-9

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  14 in total

1.  Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease.

Authors:  Zubair Baloch; Pierre Carayon; Bernard Conte-Devolx; Laurence M Demers; Ulla Feldt-Rasmussen; Jean-François Henry; Virginia A LiVosli; Patricia Niccoli-Sire; Rhys John; Jean Ruf; Peter P A Smyth; Carole A Spencer; Jan R Stockigt
Journal:  Thyroid       Date:  2003-01       Impact factor: 6.568

2.  Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland.

Authors:  M E DAILEY; S LINDSAY; R SKAHEN
Journal:  AMA Arch Surg       Date:  1955-02

3.  Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome.

Authors:  B Singh; A R Shaha; H Trivedi; J F Carew; A Poluri; J P Shah
Journal:  Surgery       Date:  1999-12       Impact factor: 3.982

Review 4.  Papillary thyroid microcarcinoma: a surgical perspective.

Authors:  George H Sakorafas; John Giotakis; Vania Stafyla
Journal:  Cancer Treat Rev       Date:  2005-07-06       Impact factor: 12.111

5.  Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma.

Authors:  K Kashima; S Yokoyama; S Noguchi; N Murakami; H Yamashita; S Watanabe; S Uchino; M Toda; A Sasaki; T Daa; I Nakayama
Journal:  Thyroid       Date:  1998-03       Impact factor: 6.568

6.  Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer?

Authors:  Daniel Repplinger; Anna Bargren; Yi-Wei Zhang; Joel T Adler; Megan Haymart; Herbert Chen
Journal:  J Surg Res       Date:  2007-10-29       Impact factor: 2.192

7.  Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome.

Authors:  F Pacini; S Mariotti; N Formica; R Elisei; S Anelli; E Capotorti; A Pinchera
Journal:  Acta Endocrinol (Copenh)       Date:  1988-11

8.  Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.

Authors:  Suk Kyeong Kim; Kee-Ho Song; So Duk Lim; Young Chang Lim; Young Bum Yoo; Ji Soo Kim; Tae Sook Hwang
Journal:  Thyroid       Date:  2009-02       Impact factor: 6.568

9.  The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland.

Authors:  S Matsubayashi; K Kawai; Y Matsumoto; T Mukuta; T Morita; K Hirai; F Matsuzuka; K Kakudoh; K Kuma; H Tamai
Journal:  J Clin Endocrinol Metab       Date:  1995-12       Impact factor: 5.958

10.  Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients.

Authors:  Elio Roti; Roberta Rossi; Giorgio Trasforini; Fiorenza Bertelli; Maria Rosaria Ambrosio; Luciano Busutti; Elizabeth N Pearce; Lewis E Braverman; Ettore C Degli Uberti
Journal:  J Clin Endocrinol Metab       Date:  2006-02-14       Impact factor: 5.958

View more
  27 in total

1.  Prediction of central lymph node metastasis in 392 patients with cervical lymph node-negative papillary thyroid carcinoma in Eastern China.

Authors:  Yingying Xiang; Kuailu Lin; Siyang Dong; L I Qiao; Qiuxiang He; Xiaohua Zhang
Journal:  Oncol Lett       Date:  2015-07-29       Impact factor: 2.967

2.  Association of XIAP and P2X7 receptor expression with lymph node metastasis in papillary thyroid carcinoma.

Authors:  Li-Qun Gu; Feng-Ying Li; Lin Zhao; Yun Liu; Qian Chu; Xun-Xiong Zang; Jian-Min Liu; Guang Ning; Yong-Ju Zhao
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

3.  Sonographic features of primary tumor as independent predictive factors for lymph node metastasis in papillary thyroid carcinoma.

Authors:  Q Wu; Y Li; Y Wang; B Hu
Journal:  Clin Transl Oncol       Date:  2015-06-04       Impact factor: 3.405

4.  Predicting the factors of lateral lymph node metastasis in papillary microcarcinoma of the thyroid in eastern China.

Authors:  Rui-chao Zeng; Quan Li; Kuai-lu Lin; Wei Zhang; Er-li Gao; Guan-li Huang; Xiao-hua Zhang; Min-hua Zheng
Journal:  Clin Transl Oncol       Date:  2012-08-08       Impact factor: 3.405

5.  Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies.

Authors:  Cosimo Durante; Sara Tognini; Teresa Montesano; Fabio Orlandi; Massimo Torlontano; Efisio Puxeddu; Marco Attard; Giuseppe Costante; Salvatore Tumino; Domenico Meringolo; Rocco Bruno; Fabiana Trulli; Maria Toteda; Adriano Redler; Giuseppe Ronga; Sebastiano Filetti; Fabio Monzani
Journal:  Thyroid       Date:  2014-05-21       Impact factor: 6.568

6.  Coexistence of thyroglobulin antibodies and thyroid peroxidase antibodies correlates with elevated thyroid-stimulating hormone level and advanced tumor stage of papillary thyroid cancer.

Authors:  Xiaoyu Wu; Yu Lun; Han Jiang; Qingwei Gang; Shijie Xin; Zhiquan Duan; Jian Zhang
Journal:  Endocrine       Date:  2013-12-14       Impact factor: 3.633

7.  Thyroid autoimmunity: is really associated with papillary thyroid carcinoma?

Authors:  Alev Selek; Berrin Cetinarslan; Ilhan Tarkun; Zeynep Canturk; Berna Ustuner; Zeynep Akyay
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-08       Impact factor: 2.503

Review 8.  The increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma.

Authors:  Roberto Vita; Antonio Ieni; Giovanni Tuccari; Salvatore Benvenga
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 6.514

9.  Dynamics of serum antithyroglobulin antibodies in patients with differentiated thyroid cancer.

Authors:  Fernanda Bueno; María Gabriela García Falcone; Mirna Angela Peñaloza; Erika Abelleira; Fabián Pitoia
Journal:  Endocrine       Date:  2019-10-24       Impact factor: 3.633

10.  Impact of clinicopathologic factors on subclinical central lymph node metastasis in papillary thyroid microcarcinoma.

Authors:  Bo-Yeon Kim; Chan-Hee Jung; Jae-Wook Kim; Seung-Won Lee; Chul-Hee Kim; Sung-Koo Kang; Ji-Oh Mok
Journal:  Yonsei Med J       Date:  2012-09       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.